Ivabradine hydrochloride Chemical Properties

Melting point:

193-196?C

alpha 

58921 +7.8°; 36521 +27.8° (c = 1% in DMSO)

storage temp. 

2-8°C

solubility 

H2O: ≥5mg/mL (warmed)

form 

powder

color 

white to beige

optical activity

[α]/D +5 to +9°, c = 1 in DMSO

Water Solubility 

H2O: ≥5mg/mL (warmed)

Merck 

14,5247

InChI

InChI=1/C27H36N2O5.ClH/c1-28(17-21-11-20-14-25(33-4)26(34-5)16-22(20)21)8-6-9-29-10-7-18-12-23(31-2)24(32-3)13-19(18)15-27(29)30;/h12-14,16,21H,6-11,15,17H2,1-5H3;1H/t21-;/s3

InChIKey

HLUKNZUABFFNQS-ZMBIFBSDSA-N

SMILES

C([C@H]1CC2=CC(OC)=C(OC)C=C12)N(C)CCCN1CCC2=CC(OC)=C(OC)C=C2CC1=O.Cl |&1:1,r|

CAS DataBase Reference

148849-67-6(CAS DataBase Reference)

Safety Information

Hazard Codes 

N

Risk Statements 

50/53

Safety Statements 

60-61

RIDADR 

UN 3077 9 / PGIII

WGK Germany 

3

HS Code 

2933.79.1500

Ivabradine hydrochloride Usage And Synthesis

Description

In an effort to develop angina agents without the unwanted negative inotropic and hypotensive effects associated with b-adrenergic blockers and calcium channel blockers, a new class of heart-rate reducing compounds that act specifically on the sinoatrial (SA) node has been explored. These bradycardic agents interact directly with the pacemaking cell of the SA node and the hyperpolarization- activated If , the primary pacemaking current. Ivabradine has evolved as a specific inhibitor of If current through its contact with f-channels on the intracellular side of the plasma membrane. As a consequence, ivabradine reduces the speed of diastolic depolarization and decreases heart rate. It has been approved for the treatment of chronic stable angina and provides a viable alternative to patients with a contraindication or intolerance of b-blockers. Evaluation is also underway for the potential treatment of ischemic heart disease. Using a patch-clamp technique on rabbit sinoatrial node cells, inhibition of If current ranged from 6% (0.03 mM) – 80% (10 mM). .

Chemical Properties

White to Off-White Solid

Originator

Servier (France)

Uses

Ivabradine hydrochloride has been used as a potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel (HCN)2 blocker in embryoid body (EB) and rat engineered heart tissue (EHT).

Uses

Ivabradine HCl, a new If inhibitor with IC 50 of 2.9 μM which acts specifically on the pacemaker activity of the sinoatrial node, is a pure heart rate lowering agent

Uses

angina therapeutic

Uses

Selective bradycardic agent with direct effect on the pacemaker If current of the sinoatrial node. Antianginal

Definition

ChEBI: A hydrochloride obtained by combining ivabradine with one molar equivalent of hydrochloric acid. Used to treat patients with angina who have intolerance to beta blockers and/or heart failure.

brand name

Procoralan

Biochem/physiol Actions

Ivabradine is used to treat chronic heart failure.

Clinical Use

Symptomatic treatment of chronic stable angina pectoris in patients with sinus rhythm Treatment of mild to severe chronic heart failure

Synthesis

1. 567 g of (S)-3-(3-(((3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl)methyl)(methyl)amino)propyl)-7,8-dimethoxy-1H-benzo[d]azepin-2(3H)-one was added to a reaction flask. 2. 2.55 L of glacial acetic acid and 141 g of palladium-carbon was added with thorough stirring and cooled to 20±5°C. 3. After evacuation, replace the nitrogen gas 3 times. 4. Control the temperature at 15~25°C and react under atmospheric pressure of hydrogen for 23 h. 5. Filter the reaction mixture through diatomaceous earth, and rinse the filter cake with glacial acetic acid. 6. Mix the filtrate with purified water and ethyl acetate, and mix thoroughly. 7. Adjust the pH to 9-10 with sodium hydroxide solution. 8. Separate the liquids, and the aqueous phase was extracted with ethyl acetate, and the organic phase was combined. 9. The organic phase was washed with saturated sodium bicarbonate solution and saturated sodium chloride solution in turn. 10. The organic phase was dried overnight, filtered, and the filter cake was rinsed with ethyl acetate. 11. The filtrate was dried by rotary evaporation to give 403.9 g of ivabradine, with a yield of 70.9% and a purity of 96.3% by HPLC. 12. To a 10L reaction flask, 402 g of ivabradine and 6L of ethyl acetate were added and stirred. 13. 6L of ethyl acetate was added to a 10L reaction flask, stirred until complete dissolution, and cooled to 0~10°C. 13. 172.2g of 20wt% hydrogen chloride isopropanol solution was added, and a large amount of white solid precipitate was observed. 14. After stirring for 1 hour, it was filtered, and the filter cake was rinsed with ethyl acetate. 15. The solid was dried in vacuum for 15 hours, and 405.1g of white solid Ivabradine HCL was obtained, with the yields of 93.5% and HPLC purity of 99.3%. 16. HPLC purity was 99.8%.

storage

Store at -20°C

References

[1] Patent: CN108424390, 2018, A. Location in patent: Paragraph 0057; 0059-0062; 0063-0069
[2] Patent: WO2011/138625, 2011, A1. Location in patent: Page/Page column 44-45
[3] Patent: WO2014/188248, 2014, A1
[4] Patent: WO2017/138017, 2017, A1. Location in patent: Page/Page column 16

Ivabradine hydrochloride(148849-67-6)Related Product Information

• METSULFURON METHYL
• Topotecan hydrochloride
• Dimethyldimethoxysilane
• 1,1-Dimethoxyethane
• Methyl acetate
• Cefradine
• Kresoxim-methyl
• Methyl salicylate
• 3-Chloropropyltrimethoxysilane
• Tribenuron methyl
• 3-Chloropropyltriethoxysilane
• 3-Aminopropyltriethoxysilane
• Ivabradine
• 1-AdaMantanethylaMine
• Polyethylene Glycol
• Dimethoxymethane
• Thiophanate-methyl
• 4,4,5A-TRIMETHYLPERHYDRO-1-BENZOXIREN-2-ONE